Parallax Volatility Advisers
CARM

Parallax Volatility Advisers’s Carisma Therapeutics CARM Stock Holding History

Parallax Volatility Advisers’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-125
Closed -$2K – 1996
2021
Q3 		$2K Buy
+125
New +$6K ﹤0.01% 1960
2019
Q1 		– Sell
-11,875
Closed -$337K – 2831
2018
Q4 		$337K Hold
11,875
– – ﹤0.01% 1607
2018
Q3 		$511K Hold
11,875
– – ﹤0.01% 1426
2018
Q2 		$463K Buy
+11,875
New +$523K ﹤0.01% 1287

Other funds holding CARM

TOTUOP
Trustees of The University of Pennsylvania Philaldelphia, Pennsylvania $297M AUM
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DCM
Deuterium Capital Management Clearwater, Florida $92.4M AUM 35% 1-Year Est. Return
WIM
Wittenberg Investment Management Carlisle, Massachusetts $269M AUM 28.17% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Parallax Volatility Advisers's CARM Position: Q1 2023 in Review

Parallax Volatility Advisers sold out of Carisma Therapeutics (CARM) in Q1 2023, closing a stake of 3,617 shares — an estimated $44.1K sold.

Parallax Volatility Advisers first reported a position in CARM in Q4 2017 and held it in 10 quarters. The position peaked at $59K in Q2 2022. 37 funds tracked by Wall St. Rank hold CARM as of Q1 2023.

  • Parallax Volatility Advisers reported no remaining Carisma Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Parallax Volatility Advisers sold 3,617 Carisma Therapeutics shares in Q1 2023, an estimated $44.1K.
  • Parallax Volatility Advisers first reported a position in Carisma Therapeutics in Q4 2017 and held it in 10 quarters.
  • Parallax Volatility Advisers's Carisma Therapeutics position peaked at $59K in Q2 2022.
  • 37 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q1 2023.

Based on Parallax Volatility Advisers's 13F filing for Q1 2023, filed 15 May 2023.